Prospect: information for the patient
Carevalan 6,25 mg/5 mg film-coated tablets
Carevalan 6,25 mg/7,5 mg film-coated tablets
Carevalan 12,5 mg/5 mg film-coated tablets
Carevalan 25 mg/5 mg film-coated tablets
Carvedilol/ivabradina
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
-If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. See section 4.
Carevalanis used in adult patients to treat:
Instead of taking carvedilol and ivabradina in separate tablets, you will be given a Carevalan tablet that contains both active ingredients at the same dose.
Carevalanis an association of two active ingredients, carvedilol and ivabradina. Carvedilol is a beta-blocker. Beta-blockers reduce heart rate, decreasing the force with which the heart muscle contracts and reducing the contraction of blood vessels in the heart, brain, and throughout the body. The specific action of ivabradina in reducing heart rate helps to:
Warnings and precautions
Consult your doctor or pharmacist before starting to takeCarevalan.
You must inform your doctor if you suffer or have suffered from any of the following conditions:
If you present any of these conditions, consult your doctor immediately before or while takingCarevalan.
Do not stop taking Carevalan suddenly, as this can cause severe changes in heart rhythm or frequency and increase the risk of a heart attack.
Athletes
This medicine contains the active ingredientcarvedilolwhich can produce a positive result in doping control tests.
Children and adolescents
Do not administer this medicine tochildren and adolescents under 18years. Available data are insufficient in this age group.
Taking Carevalan with other medicines
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medicine.
The treatment with Carevalan may be affected by other medicines. Make sure to inform your doctor if you are taking any of the following medicines, as it may be necessary to have special monitoring:
Inform your doctor that you are taking Carevalan if you are about to undergo surgery that requires anesthesia.
Carevalanwith food, drinks and alcohol
Avoid grapefruit juice during treatmentwithCarevalan.
Grapefruit or grapefruit juice may increase the active ingredients carvedilol and ivabradina in the blood and cause unpredictable side effects.
Do not drink alcohol while taking Carevalan. It may cause your blood pressure to drop too low and increase the risk of side effects.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medicine.
If you are pregnant and have taken Carevalan, consult your doctor.
Do not take Carevalan if you are fertile unless you use reliable contraceptive methods (see "Do not take Carevalan").
Do not take Carevalan if you are breastfeeding (see "Do not take Carevalan"). Talk to your doctor if you are breastfeeding or plan to start breastfeeding, as you should stop it if you take Carevalan.
Driving and using machines
Carevalanmay cause transient visual phenomena (a temporary brightness in the field of vision), (see “Possible side effects”). If this happens to you, be careful when driving or using machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
You should also be careful if you takeCarevalanwith alcohol or when changing treatment as this may affect your ability to drive or use machines.
If the tablets make you feel dizzy or tired or give you a headache, do not drive or use machines.
Carevalancontains lactose
This medicine contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with him before taking this medicine.
Carevalan contains sodium
This medicine contains less than 1mmolof sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The tablets should be taken twice a day, once in the morning and once at night during meals.
If you take more Carevalan than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested. The most likely effects are sinus arrest, dizziness, feeling of fainting, extreme fatigue, and difficulty breathing due to decreased heart rate or arrest.
If you forgot to takeCarevalan
If you forgot to take a dose of Carevalan, take the next dose at the scheduled time. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment withCarevalan
Generally, the treatment for angina pectoris or chronic heart failure is lifelong, so you should consult with your doctor before stopping this medication.
Do not stop taking Carevalan abruptlyCarevalan as this may cause severe changes in your heart rhythm or frequency and increase the risk of a heart attack. Only change the dose or interrupt treatment after consulting with your doctor.
If you think the action of Carevalan is too strong or too weak, inform your doctor or pharmacist.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may cause side effects, although not everyone will experience them.
Very common(may affect more than 1 in 10people):
Common(may affect up to 1 in 10people):
Uncommon(may affect up to 1 in 100people):
Rare(may affect up to 1 in 1,000people):
Very rare(may affect up to 1 in 10,000people):
Severe skin rash with redness, fever, blisters, or ulcers (Stevens-Johnson syndrome), severe skin rash that includes redness, peeling, and swelling of the skin that resembles severe burns (toxic epidermal necrolysis),
Frequency not known(cannot be estimated from available data):
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging, after EXP. The expiration date is the last day of the month indicated.
This medication does not require special conservation conditions.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Carevalan
Appearance of the product and contents of the package
Film-coated tablet, white, hexagonal, (6.25/5 mg) (major diagonal 7.3 mm) engraved with CI2 on one face and on the other face.
[Film-coated tablet, yellow, hexagonal, (6.25/7.5 mg) (major diagonal 7.3 mm) engraved with CI3 on one face and on the other face.]
[Film-coated tablet, white, elliptical, (12.5/5 mg) (10.6 mm x 5.3 mm) engraved with CI4 on one face and on the other face.]
[Film-coated tablet, white, octagonal, (25/5 mg) (diameter 7.8 mm) engraved with CI6 on one face and on the other face.]
The tablets are presented in calendar packaging (Aluminum/PVC blisters) of 14, 28, 56, 98, or 112 tablets.
Not all package sizes may be marketed.
Holder of the marketing authorization:
Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex
France
Responsible for manufacturing:
Les Laboratoires Servier Industrie
905, route de Saran
45520 Gidy
France
Servier (Ireland) Industries Ltd.
Gorey Road
Arklow - Co. Wicklow – Ireland
Przedsiebiorstwo Farmaceutyczne ANPHARM S.A.
ul. Annopol 6B – 03-236 Warszawa – Poland
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Laboratorios Servier S.L.
Avenida de los Madroños 33
28043 Madrid
This medicine is authorized in the member states of the European Economic Area with the following names:
Cyprus | Stovadis, επικαλυμμ?να με λεπτ? υμ?νιο δισκ?o |
Lithuania | Carivalan, plevele dengtos tabletes |
Netherlands | Carivalan, filmomhulde tabletten |
Portugal | Carivalan |
Romania | Carivalan, comprimate filmate |
Slovakia | Procodilol , filmom obalené tablety |
Spain | Carevalan, comprimidos recubiertos con película |
Last review date of this leaflet: March 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) ( http://www.aemps.gob.es/ )
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.